20 articles for S Subramanian
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
Novartis Institutes For Biomedical Research
Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.
Novartis Institutes For Biomedical Research
Discovery of Potent and Selective RSK Inhibitors as Biological Probes.
Novartis Institutes For Biomedical Research
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors.
Novartis Institutes For Biomedical Research
Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors.
Novartis Institutes For Biomedical Research
2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors.
Novartis Institutes For Biomedical Research
Identification of novel chromenone derivatives as interleukin-5 inhibitors.
Chungnam National University
Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.
Novartis Institutes For Biomedical Research
Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors.
University of Oklahoma Health Sciences Center
Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships.
University of Oklahoma Health Sciences Center
Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.
Novartis Institutes For Biomedical Research
Design and synthesis of potent RSK inhibitors.
Novartis Institutes For Biomedical Research
Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.
Novartis Institutes For Biomedical Research
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
Merck Sharp & Dohme
Exploring the Role of Residue 228 in Substrate and Inhibitor Recognition by VIM Metallo-ß-lactamases.
Louis Stokes Cleveland Veterans Affairs Medical Center